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Abstract Inappropriate drug use is an important health
problem in elderly persons. Beginning with the Beers’
criteria in the early 1990s, explicit criteria have been ex-
tensively used to measure and improve quality of drug use
in older people. This article describes the Swedish indi-
cators for quality of drug therapy in the elderly, introduced
in 2004 and updated in 2010. These indicators were de-
signed to be applied to people aged 75 years and over,
regardless of residence and other characteristics. The
indicators are divided into drug specific, covering choice,
indication and dosage of drugs, polypharmacy, drug–drug
interactions (DDIs), drug use in decreased renal function
and in some symptoms; and diagnosis specific, covering
the rational, irrational and hazardous drug use in common
disorders in elderly people. During the 10 years since in-
troduction, the Swedish indicators have several applica-
tions. They form the basis for recommendations for drug
therapy in older people, are implemented in prescribing
supports and drug utilisation reviews, are used in national
benchmarking of the quality of Swedish healthcare and
have contributed to initiatives from pensioner organisa-
tions. The indicators have also been used in several phar-
macoepidemiological studies. Since 2005, there have been
signs of improvement of the quality of drug prescribing to
elderly persons in Sweden. For example, the prescribing of
drugs that should be avoided in older persons decreased by
36 % between 2006 and 2012 in persons aged 80 years and
older. Similarly, drug combinations that may cause DDIs
decreased by 26 % and antipsychotics by 41 %. The indi-
cators have likely contributed to this.
Key Points
The Swedish indicators cover both drug- and
diagnosis-specific aspects of quality of drug therapy
in elderly persons.
Since introduction in 2004, the Swedish indicators
are widely implemented and have several
applications in healthcare and research.
Since 2005, there have been several signs of
improvement of the quality of drug prescribing to the
elderly population in Sweden.
1 Introduction
Drug use is extensive in elderly persons [1–4]. Drug ther-
apy in older people is also complicated by age-related
pharmacokinetic and pharmacodynamic changes, which
increase the sensitivity to many drugs. This, together with
the extensive use of drugs and high prevalence of comor-
bidities, substantially increase the risk of untoward effects
of drugs in old age [5, 6].
Inappropriate drug use (IDU) is an important health
problem in elderly persons and is associated with adverse
drug reactions, hospitalization, and mortality [7–11]. Pre-
vious studies have reported prevalences of IDU of
12–62 % in older people [12–16], varying greatly with
regard to participants, setting and means of measuring
IDU.
In Sweden, drug prescriptions to older people grew
significantly from the late 1980s and onwards, particularly
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over the following decade when the mean number of drugs
per person aged 80 years and older increased by over one-
third [17]. Furthermore, a study of a Swedish nationally
representative survey reported a threefold increase in the
prevalence of polypharmacy—as defined by the use of five
or more drugs—from 18 % in 1992 to 42 % in 2002 [18].
In two particularly vulnerable groups, nursing-home resi-
dents and elderly with multimorbidity, medication use was
reported to amount to approximately ten drugs per person
at the beginning of the 21st century [19–22].
Potentially, IDU was also abundant in Sweden at that
time. In a study on drug use in nursing homes in 2002, the
use of long-acting benzodiazepines and anticholinergic
drugs—both with a high risk of side effects in older per-
sons—was reported to be 15 and 20 %, respectively, and
more than one in four residents were treated with three or
more psychotropic drugs [21]. Similar results were ob-
tained from another study of 21 nursing homes in southern
Sweden the same year [20].
In the year 2000, the Swedish government commis-
sioned the Swedish National Board of Health and Welfare
to develop indicators for quality of drug therapy in the
elderly. The first version of the indicators was released in
2004 [23] and a revised version was issued in 2010 [24]. In
this review, we describe the Swedish indicators and com-
pare them with other criteria/indicators for quality of
medication treatment in elderly persons. We also describe
how they have been employed over the years in healthcare
and research, by authorities and by the elderly community
in Sweden, and how the quality of drug use has changed
over time.
2 Criteria for Quality of Drug Prescribing in Elderly
Persons
Inappropriate drug prescribing/use may be defined as the
prescribing/use of drugs where the risk outweighs the
benefit. Principally, this comprises the choice of drug, the
dosage and length of therapy, the combination of drugs
(drug duplication and drug–drug interactions [DDIs]),
drug–disease interactions [25] and, finally, underprescrib-
ing/use. The latter is also sometimes called therapy omis-
sion, i.e. the omission of drug treatment that is clinically
indicated and likely to be beneficial for the patient.
Since the beginning of the 1990s, several sets of criteria
have been developed to measure quality of drug use in older
people and to guide healthcare professionals in ensuring the
high quality and safety of drug therapy in this vulnerable
patient group. The criteria can be divided into implicit and
explicit [26, 27]. The implicit criteria are based on the
clinical judgement of the drug therapy based on information
about and from an individual patient. They rely largely on
the expertise of the examiner and are generally time-con-
suming. In contrast, the explicit criteria consist of lists of
criteria, mainly based on inappropriate drugs and drug
treatment in certain medical conditions, that are to be gen-
erally applicable to patients in a target population, for ex-
ample persons aged 65 years and older. They are intended to
be easy to use and to enable a structured way of measuring/
evaluating quality of drug use. The following sections
briefly describe some of the most important explicit criteria.
Their main features are also listed in Table 1. All of the
criteria listed below, other than the Australian Prescribing
Indicators Tool (see Sect. 2.4), were derived from a con-
sensus panel using a Delphi technique.
2.1 Beers’ Criteria
Beers’ criteria were the first explicit criteria for medication
use in the elderly, first published in 1991, and have since
then become the most cited and employed criteria in
pharmacoepidemiological studies. While the first version
[28] only comprised drugs to be avoided and doses, fre-
quencies or durations not to be exceeded, and was re-
stricted to nursing-home residents, later updates [29–31]
have included diagnosis/syndrome-specific criteria and
target the elderly in general. Beers’ criteria have been
criticised [26] mainly for being incomplete and poorly
applicable outside the US. In fact, a large proportion of the
included drugs have been reported not to be listed in
European drug formularies [32]. The most recent update
[31] shows improvements, but still lacks some aspects of
quality of drug use, such as DDIs, drug duplications and
underprescribing (therapy omissions).
2.2 McLeod’s Criteria
In parallel with the second update of the Beers’ criteria,
McLeod and coworkers in Canada developed a list of
‘inappropriate practices’, with the aim of overcoming some
of the limitations of the Beers’ criteria. The practices were
divided into three categories: drugs generally contraindi-
cated for elderly people, drug–disease interactions and
DDIs. For each practice, alternative therapies were rec-
ommended [33].
2.3 French Consensus Panel List
The French consensus panel list was the first European
criteria to be acknowledged internationally [34]. They were
partly based on previous criteria, such as the Beers’ and
McLeod’s criteria, but were much adapted to French drug
formulary and guidelines. Apart from drugs to be avoided,
they include aspects of drug duplications and drug–disease
interactions. The list also suggests alternative drugs.
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2.4 STOPP (Screening Tool of Older Person’s
Prescriptions) and START (Screening Tool to Alert
to Right Treatment)
The STOPP/START (Screening Tool of Older Person’s
Prescriptions/Screening Tool to Alert to Right Treatment)
criteria [35] were developed in Ireland, with the aim of
creating a tool that is easy to use for the prescriber in
everyday practice, yet also containing the common errors
of drug treatment in elderly people, including potentially
inappropriate medications (PIMs), drug duplications, DDIs
and prescribing omissions. The criteria are divided into 65
criteria for potentially inappropriate prescriptions (STOPP)
and 22 criteria for therapy omissions (START), each or-
ganised by physiological systems.
2.5 Australian Prescribing Indicators Tool
These criteria are largely based on medical conditions,
covering both drug–disease interactions and therapy
omissions, and include aspects on drug dosing, renal
function, DDIs and monitoring of drug effects [36]. They
also address some other relevant pieces of information; for
example, ‘blood pressure targets’, ‘risk factors for impaired
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renal function’ and ‘sources of calcium’. However, the
criteria are mainly built on Australian information sources,
such as data on common medical conditions and medica-
tions among older people, consensus documents and clin-
ical guidelines, and may therefore not be fully applicable in
other countries.
2.6 NORGEP (Norwegian General Practice) Criteria
The NORGEP (Norwegian General Practice) criteria pub-
lished in 2009, were developed for patients in general
practice and contain two lists, one about single drugs and
drug dosages and one about drug combinations, considered
potentially pharmacologically inappropriate for elderly
patients [37]. The NORGEP criteria have been criticised
for containing several drugs that are rarely used in clinical
practice [26, 27].
2.7 PRISCUS List
The PRISCUS list [38] comprises 83 drugs among a total
of 18 drug classes, rated as potentially inappropriate for
elderly patients. They do not address other aspects of
quality of drug use, but provide information regarding
possible therapeutic alternatives, as well as precautions to
be taken whenever the listed inappropriate medications are
used.
3 The Swedish Indicators for Quality of Drug Therapy
in the Elderly
3.1 Development
The starting point for the development of the Swedish
indicators were the explicit criteria available at the time,
i.e. the first version of the Beers criteria [28] and the
Canadian criteria [33]. Other sources were recommenda-
tions and guidelines from Swedish authorities and or-
ganisations, including the Swedish Medical Products
Agency, the Swedish National Board of Health and Wel-
fare, the Swedish Council on Health Technology Assess-
ment and the Swedish strategic programme against
antibiotic resistance. DDIs were to be assessed according to
the interaction database in Sweden at that time [39].
The indicators were designed to be applicable to people
aged 75 years and over, regardless of residence and other
characteristics. It was decided to include both indicators
about drug therapy regardless of diagnoses (drug-specific)
and about drug therapy in some common conditions (di-
agnosis-specific). Novelties compared with previously
published criteria at that time were the inclusion of indi-
cators about drug duplications, drug use without proper
indication and about dosage regimens. Moreover, the di-
agnosis-specific indicators were to include not only drug–
disease interactions but also aspects of adherence to treat-
ment recommendations. Thus, the indicators were sup-
posed to be not only ‘negative’, reflecting IDU, but also
‘positive’, pointing at treatment that is potentially benefi-
cial but sometimes omitted in eldercare.
The indicators were divided into (a) drug-specific,
covering choice, indication and dosage of drugs, aspects of
polypharmacy and DDIs; and (b) diagnosis-specific, cov-
ering rational, irrational and hazardous drug use in 11
common disorders in elderly people.
The indicators were validated through a consensus ap-
proach using a modified Delphi technique. The preliminary
list was assessed by an expert panel consisting of a clinical
pharmacologist, a pharmacist, two general practitioners, a
geriatrician, a geropsychiatrist and a representative from
the Swedish Medical Products Agency. After revision, a
second proposal was published on the Web and the
Swedish drug committees, heads of outpatient care and
municipality chief nurses were asked to comment on the
different indicators. Following a second revision, a final
document was published in January 2004.
This first version comprised six principal drug-specific
indicators, each containing 1–7 individual items, and 11
principal diagnosis specific indicators, each with 3–10
items on rational, irrational and hazardous drug treatment
(Table 2).
During 2008–2010 the indicators were revised and
updated. This time, the procedure was somewhat differ-
ent. The drug-specific indicators were reviewed in close
collaboration with an expert group including one clinical
pharmacologist, four pharmacists, one general practi-
tioner, one geriatrician, one nurse, two municipality chief
nurses, one pharmacoepidemiologist and one representa-
tive from the Swedish Medical Products Agency. The
diagnosis-specific indicators were reviewed by represen-
tatives from the Swedish drug committees, each of the 11
principal indicators being independently revised by two
different committees. The revision resulted in some major
changes:
• one indicator was added regarding drug use in
decreased renal function;
• one indicator was added regarding drug use and certain
symptoms that may reflect adverse drug reactions;
• one indicator was added regarding the best choice of
anxiolytic and hypnotic drugs;
• the indicator on arthrosis was replaced by an indicator
on pain treatment.
In addition many indicators were updated to meet new
recommendations, or to adapt to the current Swedish drug
formulary, and in many cases were expanded.
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The DDIs were now recommended to be assessed by
using a new database, SFINX [40], which since then has
been implemented in most computerised patient records
and other decision support systems in Sweden.
3.2 Structure
As in the first version from 2004 [23], the updated (2010)
version [24] of the Swedish indicators are divided into
drug-specific and diagnosis-specific indicators. All indica-
tors have a common structure. They refer to the proportion
of individuals using a certain inappropriate, rational, irra-
tional or hazardous medication. Moreover, they do not
specify levels of use but only state the preferred direction
(standard): ‘as low as possible’ or ‘as high as possible’
(Figs. 1, 2).
3.2.1 Drug-Specific Indicators
The updated version [24] includes nine principal drug-
specific indicators, each comprising 1–8 individual
items (Table 3; Fig. 1). Anatomical Therapeutic Che-
mical (ATC) codes are included to define the drugs or
drug groups. These indicators do not only define inap-
propriate drugs but also cover indication for drug use,
dosage regimens, maximum daily doses of some im-
portant drugs, aspects of polypharmacy, DDIs, drugs
that need dose adjustments in decreased renal function,
drugs that are implicated in some important adverse
drug reactions and some aspects on psychotropic drugs
(Table 3).
3.2.2 Diagnosis-Specific Indicators
The 2010 update [24] consists of 11 principal diagnosis-
specific indicators, each covering 2–9 items on rational,
irrational and hazardous drug treatment in common disor-
ders in old age (Table 3; Fig. 2). The indicators on haz-
ardous drug treatment represent drug–disease interactions,
whereas those on rational drug treatment can be used to
indicate therapy omissions. The indicators on irrational
drug treatment include drugs that are neither hazardous nor
beneficial with the specified diagnosis. They just represent
an unnecessary addition to the drug list and, what is worse,
may in some cases be a substitute for a better therapy. One
example of this is oral b-2-receptor agonists in chronic
obstructive pulmonary disease.
Indicator
Proportion (percent) of individuals using
• Long acting benzodiazepines (N05BA01, N05CD02, N05CD03)





Proportion (percent individuals) should be as low as possible
Fig. 1 The structure of a drug-specific indicator from the Swedish
indicators for quality of drug therapy in the elderly, exemplified by
indicator 1.1 ‘Drugs that should be avoided unless specific reasons
exist’, consisting of four items. ATC codes for the included drugs are
presented within brackets. ATC Anatomical Therapeutic Chemical
Table 2 Overview of the principal indicators in the first (2004)





1.1 Drugs that should be avoided unless specific
reasons exist
5
1.2 Drugs for which the use requires a correct and
current indication
7
1.3 Inappropriate dosage regimen 3
1.4 Inappropriate daily dose 7
1.5 Polypharmacy
Use of three or more psychotropic drugs
Drug duplication
2





2.2 Ischemic heart disease–angina pectoris 5
2.3 Heart failure 7
2.4 Chronic obstructive pulmonary disease 4
2.5 Diabetes, type 2 3
2.6 Gastroesophageal reflux disease and peptic ulcer
disease
5




2.11 Sleep disturbance 4
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4 Comparison with Other Criteria/Indicators
The Swedish indicators were relatively comprehensive,
particularly when it is considered that they were introduced
as early as 2004. Indeed, at that time only the second up-
date of the Beers’ criteria [30] and the McLeod criteria [33]
were available among the explicit criteria. The Swedish
indicators not only comprised indicators on drug–disease
interactions but also therapy omissions, both included
among the diagnosis-specific indicators. In addition, both
DDIs and drug duplications, as well as drug indications and
dosages, were addressed. With the update 2010, more
aspects on quality of medication were added; for example,
on drug use in decreased renal function.
There are some clear differences between the Swedish
indicators and other explicit criteria/indicators, in assigning
medications as appropriate or inappropriate. Some of the
drugs considered inappropriate in many other lists are even
presented as rational therapy according to the Swedish
indicators; for example, zopiclone, spironolactone and ni-
trofurantoin. Conversely, some drugs considered inappro-
priate by the Swedish indicators are not found in other lists;
for example, tramadol and propiomazine.
Among the currently available criteria/indicators, the
Swedish ones would be most comparable to the STOPP and
START criteria [35], which cover aspects on both IDU and
therapy omissions, as well as DDIs and drug duplication.
Unlike the French consensus panel list [34] and the
PRISCUS list [38], the Swedish indicator set does not
include any information about therapeutic alternatives.
However, this is intentional as one of the major aims of the
indicators was that their use should not circumscribe the
physician’s opportunity to make a qualified decision.
5 Applications of the Swedish Indicators
From the first version, the indicators were proposed to have
the following fields of applications:
• as a support for prescribing drugs to elderly people;
• in different types of local follow-ups and interventions,
for example drug utilisation reviews for elderly people
in ordinary homes or nursing homes;
• for follow-up of prescription patterns;
• for national surveys and epidemiological studies.
The indicators can thus both provide support for im-
proving the quality of older people’s drug therapy and
serve as tools for monitoring drug therapy.
Ten years after introduction, the indicators are well
established in Swedish healthcare and have brought on
several initiatives and applications along the way.
5.1 Actions from Drug and Therapeutic Committees
In 2006, the Swedish regional drug and therapeutic
committees launched a national campaign for improving
drug use in elderly people (‘Nationella kraftsamlingen’),
where one of the main objectives was to pave the way
for the indicators to have an impact on Swedish
healthcare. This resulted in not only several educational
initiatives in geriatric pharmacology for healthcare
personnel but also the creation of regional recommen-
dations for drug therapy in older people, largely based
on the indicators.
5.2 Prescribing Support
Within a year of publishing the first version of the indi-
cators, quick reference guides were developed by some
regional drug and therapeutic committees, summarising the
most clinically relevant indicators, including inappropriate
drugs—such as long-acting benzodiazepines and anti-
cholinergic drugs—and drugs that should be prescribed
with caution to elderly people; for example, non-steroidal
anti-inflammatory drugs (NSAIDs), opioids and antipsy-
chotics. Today, most Swedish counties have their own
reference guide for drug prescribing to older persons.
Later, the indicators were also implemented in some
computerised decision support systems for prescribing to
elderly patients and drug utilisation reviews [41].
Indicator
Proportion (percent) of individuals using
• Low-dose ASA, of all individuals with ischemic heart disease - angina 
pectoris
• Beta-receptor blocking agents, of all individuals with ischemic heart disease -
angina pectoris
Standard
Proportion (percent individuals) should be as high as possible
• ASA in a daily dose >75 mg, of all individuals with ischemic heart disease -
angina pectoris treated with low-dose ASA
• Organic nitrates without nitrate-free period, of all individuals with ischemic 
heart disease - angina pectoris treated with organic nitrates
• Diltiazem or verapamil, of all individuals with ischemic heart disease - angina 
pectoris and concurrent heart failure
• Diltiazem or verapamil in combination with a beta-receptor blocking agent
Standard
Proportion (percent individuals) should be as low as possible
Fig. 2 The structure of a diagnosis-specific indicator from the
Swedish indicators for quality of drug therapy in the elderly,
exemplified by indicator 2.2 ‘Ischemic heart disease–angina pectoris’.
The indicator consists of six items, the first two about rational drug
use and the remaining four about irrational or hazardous drug use.
ASA acetylsalicylic acid
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1.1 Drugs that should be avoided unless specific reasons exist 4 Long-acting benzodiazepines
Drugs with significant anticholinergic properties
Tramadol







1.3 Inappropriate dosage regimen 6 Hypnotics, [1 month of regular use
Antiepileptics [1 year without review
Antipsychotics [3 months without review
1.4 Inappropriate daily dose 6 Low-dose ASA, daily dose [75 mg
Risperidone, daily dose [1.5 mg
Oxazepam, daily dose [30 mg
1.5 Polypharmacy 3
Use of ten or more drugs
Use of three or more psychotropic drugs
Drug duplication Two or more opioids or hypnotics
1.6 Drug combinations that may lead to clinically relevant
drug–drug interactions
1 Potassium ? potassium-sparing agents
Warfarin ? NSAID
1.7 Drug use and renal function 1 Metformin, digoxin, potassium-sparing diuretics, atenolol
1.8 Drug use and certain symptoms 3
Symptomatic orthostatic hypotension Calcium channel blockers, antipsychotics
Falls Diuretics, hypnotics, antidepressants
Cognitive impairment Anticholinergic drugs, opioids, antiepileptics
1.9 Psychotropic drugs 2
Inappropriate anxiolytics and hypnotics Diazepam, propiomazine
Best-choice anxiolytics and hypnotics Oxazepam, zopiclone
2. Diagnosis-specific indicators
2.1 Hypertension 4 Hazardous: cardioselective calcium channel blocker in concurrent heart
failure
2.2 Ischemic heart disease–angina pectoris 6 Rational: low-dose ASA, daily dose 75 mg
2.3 Heart failure 9 Rational: ACE inhibitor or angiotensin-II antagonist, b-receptor blocker
Hazardous: NSAID, Cardioselective calcium channel blocker
2.4 Chronic obstructive pulmonary disease 8 Irrational: oral b-2-receptor agonist
Hazardous: non-selective b-receptor blocker
2.5 Diabetes, type 2 4 Hazardous: metformin with decreased renal function (estimated GFR
\60 ml/min), glibenclamide
2.6 GERD and peptic ulcer disease 5 Hazardous: NSAID with a history of GERD or peptic ulcer
2.7 UTI 8 Rational: pivmecillinam, nitrofurantoin or trimethoprim in UTI in women
Hazardous: quinolone antibacterials
2.8 Pain 6 Hazardous: NSAIDs—continuous treatment, tramadol
2.9 Dementia 5 Rational: cholinesterase inhibitor or memantine, if effect is ascertained
Hazardous: drugs with significant anticholinergic properties
2.10 Depression 2 Irrational: prescription of anxiolytics and hypnotics without antidepressant
treatment
2.11 Sleep disturbance 6 Hazardous: triazolam, propiomazine, alimemazine, hydroxyzine and
promethazine
NSAID non-steroidal anti-inflammatory drug, SSRI selective serotonin reuptake inhibitor, ASA acetylsalicylic acid, ACE angiotensin-converting enzyme,
GERD gastroesophageal reflux disease, UTI urinary tract infection, GFR glomerular filtration rate
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5.3 Drug Utilisation Reviews
The Swedish indicators have been extensively used for
many years in drug utilisation reviews for both nursing
home and ambulatory older persons [41, 42]. Here, both the
drug- and diagnosis-specific indicators can be used for
identifying potential drug-related problems, such as the use
of inappropriate drugs, duplicate use, DDIs and con-
traindicated drug use in some diseases. In a nursing-home
study, where an extensive part of the Swedish indicators
were used, these reviews led to marked improvements with
respect to anticholinergic drugs (part of indicator 1.1; 40 %
decrease), drug duplication (part of indicator 1.5; 30 %
decrease), DDI (indicator 1.6; 41 % decrease) and haz-
ardous drug use in some diagnoses (diagnosis-specific
indicators; 48 % decrease) [41].
5.4 National Benchmarking
Annually, since 2006 the Swedish National Board of
Health and Welfare and the Swedish Association of Local
Authorities and Regions (SALAR) have jointly published
regional comparisons of quality and efficiency in Swedish
healthcare, where the 21 counties are compared by using
more than 100 indicators [43]. Among these, five measure
the quality of drug use in older people: drugs that should be
avoided unless specific reasons exist (indicator 1.1), use of
ten or more drugs and use of three or more psychotropic
drugs (both from indicator 1.5), drug combinations that
may lead to clinically relevant drug–drug interactions
(indicator 1.6) and use of best-choice hypnotics (from
indicator 1.9). These are applied to computerised analyses
of the Swedish Prescribed Drug Register (SPDR), an in-
dividual-based register covering all dispensed prescriptions
to the whole Swedish population, of which around 740,000
people are aged 75 years and older [44].
Since 2008, a similar set of drug-specific indicators have
been analysed at the municipality and urban district level
and published annually on the Web in the so-called A¨l-
dreguiden (‘Elderly guide’), providing elderly people and
their relatives with the possibility of comparing the quality
of eldercare, including levels of inappropriate medication,
in different geographical areas of Sweden [45].
5.5 Pay for Performance
In 2010, the Swedish government and SALAR made an
agreement to support long-term improvement work with a
focus on better quality and cohesiveness of the care of the
most ill elderly persons. This included a pay for perfor-
mance model, where the Swedish counties and mu-
nicipalities were monitored with respect to different
indicators of quality of care, and awarded when attaining
the performance goals [45]. Among the indicators is one set
of three on the quality of drug use, including drugs that
should be avoided unless specific reasons exist (indicator
1.1), NSAIDs and antipsychotics (both from indicator 1.2).
During this initiative, in 2011–2014, drugs that should be
avoided unless specific reasons exist (indicator 1.1) de-
creased by 27 %, NSAIDs by 28 % and antipsychotics by
12 % in persons 75 years and older.
5.6 Initiative from Pensioner Organisations
‘Koll pa˚ la¨kemedel’ (‘Keep track of your medications’) is a
collaboration between two of the largest Swedish pensioner
organisations and one Swedish pharmacy company,
working for better drug treatment in elderly people. Their
purpose is to educate and support patients to improve their
own treatment, and one of the more appreciated products is
the ‘Ola¨mpliga listan’ (‘Inappropriate list’), derived from
indicator 1.1.
5.7 Epidemiological Studies
The Swedish indicators have been used in around 15 dif-
ferent epidemiological studies, describing quality of drug
use in the elderly population in general [44] and in nursing
homes [21, 46, 47], and investigating areas such as sex
differences [48], influence of education [3, 18], association
with institutionalisation [47], effect of multidose drug
dispensing [49, 50] and the association with hospitalisation
and mortality [7]. Among others, these studies have
demonstrated significant associations between IDU and
female sex [48], institutional living [47], low educational
attainment [3] and multidose dispensing [49].
5.8 Regulations
In 2012, the Swedish National Board of Health and Welfare
[51] launched regulations imposing healthcare providers to
offer medication reviews to all patients aged 75 years or
older, using C5 drugs. In the associated guidance [52], they
recommend the use of the indicators in these reviews.
6 Improvements in Quality of Drug Use
Since 2005, we have observed signs of improvement in the
quality of drug prescribing in the elderly population in
Sweden. In a report from the National Board of Health and
Welfare [53], analyses of the SPDR showed that the pre-
scribing of drugs that should be avoided unless specific
reasons exist (indicator 1.1) had decreased by 36 % be-
tween 2006 and 2012 in persons aged 80 years and older.
Similarly, drug combinations that may lead to clinically
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relevant drug–drug interactions (1.6) decreased by 26 %.
Among psychotropic drugs, antipsychotics reduced by
41 %, anxiolytics by 12 % and hypnotics by 10 %. In
contrast, the polypharmacy indicator use of 10 or more
drugs (1.5) did not change (11 % in both 2006 and 2012) in
this age group.
A more recent study [54] largely confirms these results.
Measurements from the SPDR between 2006 and 2013
show improvements in people aged 75 years and older,
according to all but one drug-specific indicator, covering
drugs that should be avoided unless specific reasons exist
(1.1), use of three or more psychotropic drugs (1.5) and
best-choice anxiolytics and hypnotics (1.9). However, the
indicator use of 10 or more drugs (1.5) was virtually un-
changed. The authors conclude that ‘‘prescribers appear to
be more likely to change their prescribing patterns for the
elderly than previously assumed’’ [54].
A few studies from other countries have also examined
the trend in inappropriate medication over time. In an
American study of community-dwelling elderly people
C65 years of age, IDU, as evaluated by using the Beers’
1997 criteria [29], declined from 24.8 % in 1995 to 21.3 %
in 1999, i.e. a 14 % reduction [55]. An Italian study of a
similar age group of community dwellers, over the same
time period, evaluated with Beers’ 1991 criteria [28], re-
ported a greater decrease, by 44 % (from 9.1 to 5.1 %);
however, at the same time, potentially major DDIs in-
creased by 19 % [56].
A study using a French update of the Beers 1997 [29]
criteria showed a mean annual decrease in PIM rate of
3.6 % between 1995 and 2004 [57]. However, the decrease
was only seen for two drug groups (cerebral vasodilators
and long-acting benzodiazepines).
In a more recent study from Germany, comparing 2003
and 2009, PIM prevalence evaluated by using the German
PRISCUS list, in ambulatory people aged 75 years or
more, was reduced from 29 to 25 %, corresponding to a
14 % decrease [58].
Thus, the decrease in IDU observed in the Swedish
elderly population since 2006 is largely beyond what has
been observed in other studies of long-term trends in
medication use. Although we cannot establish a causal
relationship between this positive development and the
advent of the Swedish indicators, it is reasonable to assume
that they have contributed to this positive trend.
Many types of interventions can lead to a reduction in
IDU in elderly people, ranging from educational inter-
ventions, computerised support systems, pharmacist inter-
ventions, geriatric medicine services, multidisciplinary
team reviews and regulatory policies [59]. As described
above, the Swedish indicators have, to some extent, had an
impact on all these types of interventions. Thus, the
Swedish indicators may have promoted the ‘combined
efforts’ [59] that are probably necessary to make a sus-
tainable improvement of the quality of drug treatment in
elderly patients.
7 Limitations
A general weakness of consensus-based criteria/indicators
is that they can never be fully applicable to the heteroge-
neous population of drug responders that aged people
represent. They are a crude tool and their use needs to be
adjusted to the clinical situation. Drug use deemed inap-
propriate may sometimes be indicated for the individual
patient or in a particular clinical situation, when the benefit
is estimated to outweigh the risk. This means, for example,
that this type of criteria/indicators may overestimate the
prevalence of inappropriate drug prescribing in epi-
demiological studies.
Another limitation is the general lack of information
regarding adherence to the drug therapy. This is common
to all measures of drug use, but non-adherence is more
frequent in the elderly population with polypharmacy [60],
and most likely also with IDU.
Finally, we do not know to what extent the improved
quality of drug therapy in older people in Sweden has
translated into improved health of the elderly. This needs to
be further investigated in terms of public health outcomes
in the Swedish elderly population.
8 Conclusions
The indicators on the quality of drug therapy in the elderly,
developed by the Swedish National Board of Health and
Welfare, were first published in 2004 and updated in 2010.
They comprise several aspects of quality of drug pre-
scribing, including inappropriate drugs, indication of drug
use, drug dosage, polypharmacy, drug duplications, DDIs,
drug use in decreased renal function, drug symptom/dis-
ease interactions and therapy omissions.
The indicators have been well received by Swedish
healthcare, authorities, politicians, researchers and pen-
sioner organisations. During the 10 years since their re-
lease, they have been employed in many different activities
to improve the quality of drug use in elderly persons, in-
cluding prescribing support, drug utilisation reviews and
national benchmarking. They also form the basis for rec-
ommendations on drug treatment in old age, several sci-
entific publications, and have promoted many educational
initiatives in this area, both for healthcare personnel and for
older persons and their relatives.
During this time, several measures of the quality of drug
use in the Swedish elderly population have shown
Swedish Indicators for Quality of Drug Therapy in Older Persons 197
significant improvements; for example, a decreased
prevalence of drugs that should be avoided, drug combi-
nations that may lead to DDIs and several types of psy-
chotropic drugs.
Therefore, the Swedish indicators may be seen as a
successful national initiative that has translated into local
initiatives, research in geriatric pharmacoepidemiology,
and contributed to better drug treatment in old age.
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